Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Azacitidine Use in the Real World Does Not Replicate AZA-001 Results in Higher Risk MDS/Low Blast Count AML: An Audit of 1101 Patients in the Cancer Care Ontario Registry

Lee Mozessohn, MD FRCPC, Matthew C. Cheung, MD SM, FRCPC, Saber Fallahpour, PhD, Tripat Gill, MSc PH, Asmaa Maloul, PhD, Liying Zhang, PhD, Olivia Lau, Rena Buckstein, MD

Blood (2016) 128 (22): 4338.

https://doi.org/10.1182/blood.V128.22.4338.4338

Published: 2016

Journal Articles

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

Neil L Berinstein, MD, Nancy M Pennell, BSc, Rashmi Weerasinghe, Matthew C. Cheung, MD SM, FRCPC, Eugenia Piliotis, MD FRCP, MD, Kevin R Imrie, MD, Mary-Anne Cussen, Rena Buckstein, MD, Zeina Ghorab, Ellen Miles, Marciano D. Reis, MD

Blood (2016) 128 (22): 1794.

https://doi.org/10.1182/blood.V128.22.1794.1794

Published: 2016

Journal Articles

ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis

Abi Vijenthira, MD, Matthew C Cheung, MD, Chai Wye Phua, MD, Kelvin Chan, Joanna Graczyk, MD, Rena Buckstein, MD, Anca Prica, MD

Blood (2016) 128 (22): 1183.

https://doi.org/10.1182/blood.V128.22.1183.1183

Published: 2016

Journal Articles

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Tanya Skamene, MD, Wenyu Jiang, PhD, Ralph M. Meyer, MD, Michael Crump, MD, John Kuruvilla, MD, C. Tom Kouroukis, MD MSc, FRCPC, Stefano Luminari, Stephen Couban, MD, Matthew C. Cheung, MD SM, FRCPC, David A Rizzieri, MD, Peter G Bardy, MBBS, FRACP, FRCPA, Joseph Pater, MD MSc, Marina S. Djurfeldt, MSc, Lois E. Shepherd, MD, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 690.

https://doi.org/10.1182/blood.V128.22.690.690

Published: 2016

Journal Articles

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission

Matthew C Cheung, MD SM, FRCPC, Nicole Mittmann, PhD, Craig Earle, MD MSc., Farah Rahman, Ning Liu, Simron Singh, MD MPH, FRCPC

Blood (2016) 128 (22): 692.

https://doi.org/10.1182/blood.V128.22.692.692

Published: 2016

Journal Articles

Assessment of Value Using the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) Frameworks for Novel Therapies for the Hematologic Malignancies

Matthew C Cheung, MD SM, FRCPC, Sierra Cheng, Erica McDonald, Vanessa Arciero, Mahin Qureshi, Kelvin Chan

Blood (2016) 128 (22): 3578.

https://doi.org/10.1182/blood.V128.22.3578.3578

Published: 2016

Journal Articles

Predictors for ICU Admission and Clinical Outcomes of Malignant Hematology Patients Admitted to Critical Care Units

Daniel Jacobson, BSc. (C), Nicholas Chiu, MD(C), Matthew C. Cheung, MD SM, FRCPC, Robert Fowler, MD MDM, M.Sc., Rena Buckstein, MD

Blood (2016) 128 (22): 3595.

https://doi.org/10.1182/blood.V128.22.3595.3595

Published: 2016

Journal Articles

Adjusting For Drug Wastage In Economic Evaluations Of New Therapies For Hematologic Malignancies: A Systematic Review Of The Literature and Implications

Matthew C. Cheung, MD, Maureen E. Trudeau, Anca Prica, MD, Rena Buckstein, MD, Kelvin KW Chan, MD

Blood (2013) 122 (21): 2928.

https://doi.org/10.1182/blood.V122.21.2928.2928

Published: 2013

Journal Articles

Frontline Rituximab Monotherapy Induction Versus a Watch and Wait Approach For Asymptomatic Advanced Stage Follicular Lymphoma: A Cost-Effectiveness Analysis

Anca Prica, MD, Kelvin KW Chan, MD, Matthew C Cheung, MD

Blood (2013) 122 (21): 2941.

https://doi.org/10.1182/blood.V122.21.2941.2941

Published: 2013

Journal Articles

Predictors Of Delay In Diagnosis and Treatment In Diffuse Large B-Cell Lymphoma and Impact On Survival

Anna Nikonova, MD.CM, Rena Buckstein, MD, FRCPC, Hany Giurgis, MD, FRCPC, Matthew C Cheung, MD, FRCPC

Blood (2013) 122 (21): 4322.

https://doi.org/10.1182/blood.V122.21.4322.4322

Published: 2013

Journal Articles

Cost-Utility Of Bortezomib In Induction Treatment Prior To Autologous Stem-Cell Transplantation (ASCT) In Previously Untreated Multiple Myeloma Patients In Canada

Tom Kouroukis, MD, MSc, FRCPC, Darrell White, MD, MSc, FRCPC, FACP, Morgan Kruse, BA, Donna Lawrence, MSc, Cristina Trambitas, BSc MBA, Matthew C. Cheung, MD, FRCPC

Blood (2013) 122 (21): 1735.

https://doi.org/10.1182/blood.V122.21.1735.1735

Published: 2013

Journal Articles

Shelf-Life Extension Of Azacitidine: A Cancer Centre Experience On Waste and Cost Reduction In The Treatment Of Myelodysplastic Syndromes

Hany R. Guirguis, MD, Flay Charbonneau, BSc Pharm, Ivan Tyono, BSc Pharm, Matthew C. Cheung, MD, Rena Buckstein, MD

Blood (2013) 122 (21): 1749.

https://doi.org/10.1182/blood.V122.21.1749.1749

Published: 2013

Journal Articles

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Blood (2013) 122 (21): 155.

https://doi.org/10.1182/blood.V122.21.155.155

Published: 2013

Journal Articles

Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature

Anca Prica, MD, Ariella Pratzer, Matthew C Cheung, MD, Kim Thompson, Eugenia Piliotis, MD, Neil L Berinstein, MD, Kevin R. Imrie, MD, Rahim Pradhan, Anju Vyas, David Good, MD, Liying Zhang, PhD, Rena Buckstein, MD

Blood (2013) 122 (21): 5093.

https://doi.org/10.1182/blood.V122.21.5093.5093

Published: 2013

Journal Articles

Publication Patterns of Cancer Cost-Effectiveness Studies Presented at the American Society of Hematology: Timeliness of Publication, Quality and Possible Bias.

Lee Mozessohn, MD, Kelvin KW Chan, MD, MSc, FRCPC, Matthew C Cheung, MD, SM, FRCPC

Blood (2010) 116 (21): 3816.

https://doi.org/10.1182/blood.V116.21.3816.3816

Published: 2010

Journal Articles

Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin's Lymphoma Development and Survival.

Linda R Taggart, MD, Pierre K Isogai, B.Sc, Nancy Risebrough, B.A., Nicole Mittmann, MSc, PhD, Anita R Rachlis, MD, Kevin R Imrie, MD, Matthew C Cheung, MD

Blood (2009) 114 (22): 1916.

https://doi.org/10.1182/blood.V114.22.1916.1916

Published: 2009

Journal Articles

Rituximab Based Regimen May Decrease the Incidence of CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma.

Mervat Mahrous Mohamed, MD, Rena Buckstein, MD, FRCPC, Eugenia Piliotis, MD, Matthew C Cheung, MD, Neil Berinstein, MD

Blood (2009) 114 (22): 4770.

https://doi.org/10.1182/blood.V114.22.4770.4770

Published: 2009

Journal Articles

Transfusion Dependence and Low Hemoglobin Have the Greatest Impact On Quality of Life (QOL) in MDS Patients - a Tertiary Care Cross Sectional and Longitudinal Study.

Rena Buckstein, MD, Shabbir Alibhai, MD, Adam Lam, Liying Zhang, Alex Mamedov, Matthew C Cheung, MD, Jeannie Callum, MD, Eugenia Piliotis, MD, Janey Tsiao, MD, Yulia Lin, MD, Richard A. Wells, MD, DPhil

Blood (2009) 114 (22): 2500.

https://doi.org/10.1182/blood.V114.22.2500.2500

Published: 2009

Journal Articles

Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis against Febrile Neutropenia in Lymphoma Patients Receiving R-CHOP Chemotherapy.

Nina Lathia, MSc, Pierre K Isogai, B.Sc, Scott Walker, MScPhm, Matthew C Cheung, MD, Murray Krahn, MD, MSc, Carlo DeAngelis, PharmD, Nicole Mittmann, MSc, PhD

Blood (2009) 114 (22): 2475.

https://doi.org/10.1182/blood.V114.22.2475.2475

Published: 2009

Journal Articles

Iron Overload and Haematopoiesis in MDS: Does Blood Transfusion Promote Progression to AML?

Lap Shu Alan Chan, Rena Buckstein, MD, Marciano D. Reis, MD, Alden Chesney, II, MD, Adam Lam, Matthew C Cheung, MD, Eugenia Piliotis, MD, Lilly Chunhong Gu, MD, PhD, Richard A. Wells, MD, DPhil

Blood (2008) 112 (11): 2685.

https://doi.org/10.1182/blood.V112.11.2685.2685

Published: 2008

NARROW

Azacitidine Use in the Real World Does Not Replicate AZA-001 Results in Higher Risk MDS/Low Blast Count AML: An Audit of 1101 Patients in the Cancer Care Ontario Registry

Risk Adjusted Management of Newly Diagnosed High and Intermediate FLIPI Follicular Lymphoma Using (90)Y Ibritumomab Tiuxetan

ABVD Versus Combination Baseline Beacopp/Escalated Beacopp in the Treatment of Newly Diagnosed Advanced-Stage Hodgkin Lymphoma: A Decision Analysis

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in Long-Term Remission

Assessment of Value Using the American Society of Clinical Oncology (ASCO) and European Society of Medical Oncology (ESMO) Frameworks for Novel Therapies for the Hematologic Malignancies

Predictors for ICU Admission and Clinical Outcomes of Malignant Hematology Patients Admitted to Critical Care Units

Adjusting For Drug Wastage In Economic Evaluations Of New Therapies For Hematologic Malignancies: A Systematic Review Of The Literature and Implications

Frontline Rituximab Monotherapy Induction Versus a Watch and Wait Approach For Asymptomatic Advanced Stage Follicular Lymphoma: A Cost-Effectiveness Analysis

Predictors Of Delay In Diagnosis and Treatment In Diffuse Large B-Cell Lymphoma and Impact On Survival

Cost-Utility Of Bortezomib In Induction Treatment Prior To Autologous Stem-Cell Transplantation (ASCT) In Previously Untreated Multiple Myeloma Patients In Canada

Shelf-Life Extension Of Azacitidine: A Cancer Centre Experience On Waste and Cost Reduction In The Treatment Of Myelodysplastic Syndromes

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Rituximab Improves Overall Survival In Patients Treated With CODOX-M/IVAC For Burkitt Lymphoma (BL) and B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL: A Single Center Experience and Review Of The Literature

Publication Patterns of Cancer Cost-Effectiveness Studies Presented at the American Society of Hematology: Timeliness of Publication, Quality and Possible Bias.

Trends in the Incidence of HIV-Related Hematologic Malignancies in the Era of Combination Antiretroviral Therapy and Predictors of HIV-Related Non-Hodgkin's Lymphoma Development and Survival.

Rituximab Based Regimen May Decrease the Incidence of CNS Relapse in Patients with Diffuse Large B-Cell Lymphoma.

Transfusion Dependence and Low Hemoglobin Have the Greatest Impact On Quality of Life (QOL) in MDS Patients - a Tertiary Care Cross Sectional and Longitudinal Study.

Cost-Effectiveness of Filgrastim and Pegfilgrastim as Primary Prophylaxis against Febrile Neutropenia in Lymphoma Patients Receiving R-CHOP Chemotherapy.

Iron Overload and Haematopoiesis in MDS: Does Blood Transfusion Promote Progression to AML?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only